Jiayu Liang1, Zhihong Liu1, Liang Zhou1, Yongquan Tang2, Chuan Zhou1, Kan Wu1, Fuxun Zhang1, Fan Zhang1, Xin Wei1, Yiping Lu3, Yuchun Zhu4. 1. Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China. 2. Department of Pediatric Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China. 3. Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China. yipinglu@163.com. 4. Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China. mmaalleee@126.com.
Abstract
BACKGROUND: Adrenocortical carcinoma (ACC) is a rare cancer with poor survival. We sought to identify prognostic factors and assess its clinical utility in postoperative management of nonmetastatic ACC. METHODS: We included 65 patients who underwent adrenalectomy and clinicopathological diagnosed as European Network for the Study of Adrenal Tumors (ENSAT) stage I-III ACC in our center from 2009 to 2017. Potential clinicopathological parameters were selected. The prognostic correlation, including overall survival (OS) and recurrence-free survival (RFS), was analyzed using Kaplan-Meier method and univariate and multivariate Cox model. RESULTS: The 2-year and 5-year post-surgery survival rate were 54.6% (95%CI: 42.5-70.1%) and 33.5% (95%CI: 22.3-50.6%), respectively. 46 (70.8%) cases were symptomatic ACC. Tumor-related or hormone-related symptom was identified as independent prognostic factor in OS (HR = 5.5, 95%CI: 1.87-16.16) and RFS (HR = 3.62, 95%CI: 1.28-10.24). Higher tumor grade (Weiss score > 6 or Ki67 index ≥ 20%) was independently associated with poor OS (HR = 4.73, 95%CI: 2.15-10.43). R status (R1/R2/Rx) was independently correlated with worse RFS (HR = 2.56, 95%CI:1.21-5.43). Accordingly, patients with higher GRAS (Grade, R status, age, and symptoms) score were more likely to have poor prognosis (OS: HR = 2.7, 95%CI: 1.43-5.11 and RFS: HR = 3.31, 95%CI: 1.68-6.52, respectively). CONCLUSIONS: Symptoms, higher tumor grade and positive/unknown R status were independent risk factors in stage I-III ACC. Comprehensive consideration of GRAS parameters may optimize the prognostic assessment for postoperative patients.
BACKGROUND:Adrenocortical carcinoma (ACC) is a rare cancer with poor survival. We sought to identify prognostic factors and assess its clinical utility in postoperative management of nonmetastatic ACC. METHODS: We included 65 patients who underwent adrenalectomy and clinicopathological diagnosed as European Network for the Study of Adrenal Tumors (ENSAT) stage I-III ACC in our center from 2009 to 2017. Potential clinicopathological parameters were selected. The prognostic correlation, including overall survival (OS) and recurrence-free survival (RFS), was analyzed using Kaplan-Meier method and univariate and multivariate Cox model. RESULTS: The 2-year and 5-year post-surgery survival rate were 54.6% (95%CI: 42.5-70.1%) and 33.5% (95%CI: 22.3-50.6%), respectively. 46 (70.8%) cases were symptomatic ACC. Tumor-related or hormone-related symptom was identified as independent prognostic factor in OS (HR = 5.5, 95%CI: 1.87-16.16) and RFS (HR = 3.62, 95%CI: 1.28-10.24). Higher tumor grade (Weiss score > 6 or Ki67 index ≥ 20%) was independently associated with poor OS (HR = 4.73, 95%CI: 2.15-10.43). R status (R1/R2/Rx) was independently correlated with worse RFS (HR = 2.56, 95%CI:1.21-5.43). Accordingly, patients with higher GRAS (Grade, R status, age, and symptoms) score were more likely to have poor prognosis (OS: HR = 2.7, 95%CI: 1.43-5.11 and RFS: HR = 3.31, 95%CI: 1.68-6.52, respectively). CONCLUSIONS: Symptoms, higher tumor grade and positive/unknown R status were independent risk factors in stage I-III ACC. Comprehensive consideration of GRAS parameters may optimize the prognostic assessment for postoperative patients.
Authors: J Lindholm; S Juul; J O Jørgensen; J Astrup; P Bjerre; U Feldt-Rasmussen; C Hagen; J Jørgensen; M Kosteljanetz; L Kristensen; P Laurberg; K Schmidt; J Weeke Journal: J Clin Endocrinol Metab Date: 2001-01 Impact factor: 5.958
Authors: Barbra S Miller; Paul G Gauger; Gary D Hammer; Thomas J Giordano; Gerard M Doherty Journal: Langenbecks Arch Surg Date: 2010-08-09 Impact factor: 3.445
Authors: Sherita H Golden; Karen A Robinson; Ian Saldanha; Blair Anton; Paul W Ladenson Journal: J Clin Endocrinol Metab Date: 2009-06 Impact factor: 5.958
Authors: Alfredo Berruti; Martin Fassnacht; Harm Haak; Tobias Else; Eric Baudin; Paola Sperone; Matthias Kroiss; Thomas Kerkhofs; Andrew R Williams; Arianna Ardito; Sophie Leboulleux; Marco Volante; Timo Deutschbein; Richards Feelders; Cristina Ronchi; Salvatore Grisanti; Hans Gelderblom; Francesco Porpiglia; Mauro Papotti; Gary D Hammer; Bruno Allolio; Massimo Terzolo Journal: Eur Urol Date: 2013-11-14 Impact factor: 20.096
Authors: Thomas M A Kerkhofs; Rob H A Verhoeven; Jan Maarten Van der Zwan; Jeanne Dieleman; Michiel N Kerstens; Thera P Links; Lonneke V Van de Poll-Franse; Harm R Haak Journal: Eur J Cancer Date: 2013-04-03 Impact factor: 9.162
Authors: Kara K Rossfeld; Shishir K Maithel; Jason Prescott; Tracy S Wang; Ryan C Fields; Sharon M Weber; Jason K Sicklick; Adam C Yopp; Quan-Yang Duh; Carmen C Solorzano; Konstantinos I Votanopoulos; Ioannis Hatzaras; George A Poultsides; Lawrence A Shirley Journal: J Surg Oncol Date: 2018-10-17 Impact factor: 3.454
Authors: Y S Elhassan; B Altieri; S Berhane; D Cosentini; A Calabrese; M Haissaguerre; D Kastelan; M C B V Fragoso; J Bertherat; A Al Ghuzlan; H Haak; M Boudina; L Canu; P Loli; M Sherlock; O Kimpel; M Laganà; A J Sitch; M Kroiss; W Arlt; M Terzolo; A Berruti; J J Deeks; R Libé; M Fassnacht; C L Ronchi Journal: Eur J Endocrinol Date: 2021-11-30 Impact factor: 6.664